DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial.

Author(s): Ondo WG, Shinawi L, Davidson A, Lai D

Affiliation(s): Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA. wondo@bcm.tmc.edu

Publication date & source: 2011-03, Parkinsonism Relat Disord., 17(3):156-9. Epub 2010 Dec 30.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

OBJECT: To perform an exploratory study evaluating memantine for several common non-motor problems in Parkinson's disease. METHODS: We conducted a single center, double-blind, placebo controlled pilot trial of memantine, titrated to 20 mg/day, in PD subjects. Inclusion criteria were intentionally broad and included both fluctuating and non-fluctuating patients. After baseline assessments, subjects (N = 40) were randomized to drug and placebo groups. They received a battery of traditional and non-motor assessments. After a safety call (2 weeks after baseline) they returned for identical assessments at week 8. An 8-week open label extension was started if desired. RESULTS: Subject demographics (age 69.1 +/- 7.8; 24 males), were similar in the drug and placebo groups. Four dropped from the study while on drug vs. none on placebo. Two of 36 remaining dropped out over the 8-week open label section. Of the 34 who completed the final open label visit, 24 elected to be prescribed memantine after the study. During the controlled trial, there was no significant change in UPDRS section I or II, Epworth sleepiness scale, fatigue severity scale, Hamilton depression scale, Conner adult inventory, PD Quality of Life-39, or clinical global impressions. UPDRS "on" motor scores tended to improved, p = 0.19. CONCLUSION: Memantine was well tolerated in PD; however, specific measures of sleepiness, fatigue, depression, and attention did not significantly improve. The majority of subjects elected to stay on the drug after the open label extension suggesting some unassessed benefit. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017